Cunnane, Stephen C.
Sieber, Cornel C.
Swerdlow, Russell H.
Cruz-Jentoft, Alfonso J.
Funding for this research was provided by:
Nestlé Health Science
Article History
Received: 1 April 2021
Accepted: 22 June 2021
First Online: 5 July 2021
Declarations
:
: All authors received consulting fees from Nestlé Health Science and were compensated for their participation in reviewing the EuGMS Congress Proceedings report at a fair market rate. In addition, Cornel C. Sieber, MD, PhD, has either received speaker fees or was involved in consulting or research projects for Abbott, Braun, Danone, Fresenius, Nestlé, Novartis, Nutricia, Pfizer, and Roche. Russell H. Swerdlow, MD, is supported by the National Institute on Aging P30AG035982. Alfonso J. Cruz-Jentoft, MD, PhD, has received speaker fees from Abbott Nutrition, Fresenius, Nestlé, and Nutricia. He has been member of advisory boards for Abbott Nutrition, Nestlé, and Pfizer, and has worked on research projects with Abbott Nutrition and Nutricia. Stephen C. Cunnane, PhD, declares that in the past 3 years, he has consulted for and has received honoraria, test products, and/or research funding from Bulletproof and Nestlé Health Science. He is the founder of Senotec and co-inventor of a patented medium-chain triglyceride formulation. His research is also supported by the Canadian government organizations, Canadian Foundation for Innovation (CFI), Natural Sciences and Engineering Research Council of Canada (NSERC), MITACS, the Québec government (Fonds de la Recherche du Québec-Santé), and several nonprofit organizations (Alzheimer Society of Canada, Alzheimer’s Association USA, Université de Sherbrooke). Medical writing was also funded by Nestlé Health Science.
: Not applicable.
: Not applicable.
: All authors approved the manuscript and provided their consent for publication submission.